PrestoDoctor founders Kyle & Rob here, and we’ve got some exciting news to share.
Cannabis Sativa, Inc. (OTCQB:CBDS) has acquired a 51% stake in PrestoDoctor.
Cannabis Sativa President David Tobias says:
We are pleased to bring PrestoDoctor on board as a subsidiary of Cannabis Sativa. Combining our resources should be a great benefit to both companies. We are eager to assist PrestoDoctor in the roll out of their medical marijuana programs in several new states this year, and hope to see the continued growth of PrestoDoctor for years to come. We believe telemedicine is the future.
What does this mean for current or future PrestoDoctor patients? We will double down on our commitment to world-class customer service and support (we’re the #1-rated service for health and wellness online!), so don’t worry about that changing. Our partnership with Cannabis Sativa will allow us to reach new markets and more people faster, so you will be seeing us in new states (and maybe even new countries) very soon.
We want to extend a big thank you to all of our supporters along the way. It’s been an outstanding experience, and we’re looking forward to the next few years of helping patients gain access to to the medicine they need.
– Kyle & Rob
About Cannabis Sativa, Inc.:
Cannabis Sativa, Inc. (“CBDS”) is engaged in the licensing of cannabis related intellectual property, marketing and branding for cannabis based products and services, operation of cannabis related technology services, and ancillary business activities. CBDS licenses the “hi” and “White Rabbit” brands, holds a U.S. patent on the Ecuadorian Sativa strain of Cannabis, owns patent pending and trade secret formulas and processes, offers the hi benefits discount pharmacy card, and operates the ibudtender.com information platform. In addition, CBDS seeks strategic partners for acquisition of operating companies, intellectual property and other assets which fit within the CBDS corporate vision.
This press release contains “forward-looking statements.” Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Underlying assumptions include without limitation, the ongoing enactment of legislation favorable to the production of and the commercialization of cannabis products and the Company’s success in capitalizing on that legislation. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.